pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
148
stories
Aug 6, 26
BioVie shares halve on murky Parkinson’s disease readout
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 31, 26
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 30, 26
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
Jul 30, 26
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
Jul 29, 26
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
Jul 28, 26
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
Jul 28, 26
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
Jul 28, 26
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
fiercebiotech
Jul 28, 26
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 27, 26
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
Jul 27, 26
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
Jul 24, 26
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
Jul 24, 26
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
Jul 22, 26
6 companies hiring in Cambridge now
biospace
Jul 22, 26
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 21, 26
Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
biospace
Jul 20, 26
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
Jul 20, 26
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal
endpoints
Jul 18, 26
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
Jul 17, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jul 16, 26
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jul 14, 26
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
← prev
page 4 of 5
next →
